Thursday 16 October, 2025
Introduction: The pharmacokinetic (PK) model development for nasal delivery is a challenging process without adequate literature reports. Intravenous PK models…
Read moreAbstracts
Dabrafenib and Trametinib dose optimization in 6-17 year old tumor agnostic patients based on established efficacy surrogate targets in adults
Thursday 16 October, 2025
Objectives: To support pediatric dose selection of solid formulations of dabrafenib and trametinib in 6 to 17 year old patients…
Read moreMechanism-based pharmacokinetic-pharmacodynamic modeling of short-term erythroferrone response and long-term efficacy of erythropoietin in chemotherapy-induced anemia rats
Thursday 16 October, 2025
Introduction: Chemotherapy-induced anemia is commonplace among cancer patients. Recombinant human erythropoietin (rHuEPO) has been used to treat CIA patients with hemoglobin…
Read morePemba Island, Tanzania, versus Côte d’Ivoire – Population effect on apparent clearance of active albendazole metabolites
Thursday 16 October, 2025
Introduction: Soil transmitted helminth infections affect an estimated 24% of the world’s population [1]. Communities with poor access to sanitation and…
Read moreModelling selective cell targeting through avidity to inform bispecific antibody discovery and development
Thursday 16 October, 2025
Objectives: Avidity is the phenomena referring to an increasing probability of a bivalent binder to bind a second target after…
Read moreInfluence of interoccasion variability on parameter estimates of a population pharmacokinetic model under various sparse study designs
Thursday 16 October, 2025
Objectives:Sampling schemes to inform pharmacokinetic (PK) modelling in phase II clinical studies are sparse. Typically, sampling is performed in a…
Read moreExternal evaluation of pharmacometric models of moxifloxacin for Bayesian forecasting in the treatment of tuberculosis
Thursday 16 October, 2025
Objectives: Personalization of drug therapy can be realized using therapeutic drug monitoring (TDM). A personalized dose for an individual can be…
Read moreEvaluation of QT Prolongation During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)
Thursday 16 October, 2025
Introduction: M2, the main metabolite of bedaquiline (BDQ), is associated with QTc prolongation. Assessing QT liabilities in persons with active…
Read moreOptimal longitudinal QT interval correction method considering changes in heart rate variability in patients treated for drug-resistant tuberculosis
Thursday 16 October, 2025
Objective: Active tuberculosis (TB) is associated with tachycardia which generally diminishes with treatment. As the typical heart rate (HR) in a…
Read moreA circular PK/PD/PK model explains the exposure of bulevirtide and bile salts in adult patients with chronic hepatitis D
Thursday 16 October, 2025
Objectives: Chronic hepatitis D (CHD) is a rare inflammatory liver disease caused by hepatitis delta virus (HDV). It is the…
Read more